Evidence map›Paper›PMID 33604804›Full record

ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2021

Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL in Patients with T2D Uncontrolled on NPH or Premixed Insulins as Part of Routine Clinical Practice in Bulgaria: ToUPGRADE Study.

Zdravko Kamenov, Veselina Pehlivanova, Tsvetodara Kuneva, Kiril Kirilov, Roza Bobeva, Julija Stoykova, Svetla Mihalevska

Open access · goldAbstract read
In one paragraph

Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Zdravko KamenovUniversity Hospital "Aleksandrovska", Medical University of Sofia, Sofia, Bulgaria. zkamenov@hotmail.com.ORCID http://orcid.org/0000-0002-4829-9449
Veselina PehlivanovaSanofi, Sofia, Bulgaria.
Tsvetodara KunevaDiagnostic-Consultative Centre 1, Ruse, Bulgaria.
Kiril KirilovMedical Ambulatory Centre "Asklepii", Dupnitsa, Bulgaria.
Roza BobevaMultiprofile Hospital for Active Treatment "Dr. Ivan Seliminski", Sliven, Bulgaria.
Julija StoykovaMultiprofile Hospital for Active Treatment, Pleven, Bulgaria.
Svetla MihalevskaSanofi, Sofia, Bulgaria.
Alexandrovska Hospital · BGNational Institute of Emergency Medicine "Pirogov" · BG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe aim of this study is to demonstrate the real-life effectiveness and safety of insulin glargine 300 U/mL (Gla-300) in patients with type 2 diabetes (T2D) previously uncontrolled on NPH ± prandial insulin or premixed insulins in routine clinical practice in Bulgaria.

methodsThis was a 24-week prospective, observational study performed in 40 inpatient and outpatient sites across the country.

resultsA total of 286 patients were included in the study. The mean age (± SD) was 61.2 ± 10.0 years with duration of diabetes of 11.64 ± 7.5 years and body mass index (BMI) of 32.1 ± 5.7 kg/m

conclusionsIn real-life settings, Gla-300 significantly improved glycaemic control and insulin treatment satisfaction in people with T2D who were inadequately controlled with NPH ± prandial insulin or premixed insulin analogues. Improvement of glycaemic control was associated with a very low risk of hypoglycaemia and with significant weight loss irrespective of the previous insulin regimen.

Indexed as

Basal insulinsInsulin glargine 300 U/mLObservational studyReal-life effectivenessRoutine clinical practiceToUPGRADEType 2 diabetes

Identifiers

PMID33604804
PMCPMC7947095
OpenAlexW3130557029

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.